ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0808

Lower Serum MIP-1β Level Is Associated with CsDMARDs Response in Patients with Early Rheumatoid Arthritis

Isaac Cheng1, Ho So2, Martin Li1, Evelyn Chow1, Chun Kwok Wong1 and Lai-Shan Tam3, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2CUHK, Hong Kong, China, 3Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)

Meeting: ACR Convergence 2021

Keywords: biomarker, rheumatoid arthritis, treatment response

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The use of treat-to-target (T2T) strategy in managing early rheumatoid arthritis (ERA) had been highly advocated in the past decades. Various international guideline utilized a stepwise approach starting with conventional synthetic disease modification anti-rheumatic drug (csDMARDs), and eventually escalate to biologic/targeted synthetic DMARDs (b/tsDMARDs) when the target is not met. The response rate to csDMARDs varies among individuals. Currently, there are limited biomarker data in predicting csDMARDs response. If certain biomarker could predict non-response towards csDMARDs, would early initiation of b/tsDMARDs improve disease prognosis remained uncertain.

Methods: This is a 6-month pilot prospective discovery cohort in patients with ERA. Patients received T2T treatment according to a standardized protocol with every 3-monthly follow up. Patients who achieved simplified disease activity index (SDAI) remission at month 6 is defined as csDMARDs responder. Serum blood sample was collected at baseline and 48 cytokines and chemokines Bio-Rad Bioplex assay was performed.

Results: Twenty-seven patients (age: 55±15 years; female: 21(78%)) who had completed month 6 follow up were included in the current analysis. All patient received csDMARDs treatment. After 6 months, significant improvement in disease activity was observed (SDAI: 24.4±8.3 at baseline vs 8.0±6.5 at month 6, p< 0.001). One third of them (9/27, 33%) achieved SDAI remission at month 6 and were regarded as csDMARDs responder (DR). Patients in DR+ group were older, had lower pain score and higher Erythrocyte sedimentation rate (ESR) (Table 1). There were no statistically difference between the use of drugs across the two groups during study period. Macrophage inflammatory protein-1β (MIP-1β) is a proinflammatory chemokine produced by macrophages. Baseline serum level of MIP-1β were dateable in all patients, and the level was significantly lower in DR (DR: 393±21 ng/ml vs non-DR: 437 ±46 ng/ml, p=0.012). Using multivariate logistic regression, lower MCP-1 was significantly associated with csDMARDs response (OR=0.87, 95%CI: 0.77 to 0.99, p=0.034) after adjustment of age, ESR and pain score at baseline. MIP-1β were also positively correlated with rheumatoid factor (r=0.559, p=0.02) at baseline and SDAI at month 6 (r=0.412, p=0.012).

Conclusion: Lower serum level of MIP-1β was associated with csDMARDs response in patients with ERA. Further validation will testify current findings.

Table 1 – Baseline clinical features and disease activity in csDMARDs responder and non-responder
ACCP – anticyclic citrullinated peptide; VAS – visual analogue scale; ESR – erythrocyte sedimentation rate; CRP – C-reactive protein; DAS- disease activity index; CDAI – clinical disease activity index; SDAI – simplified disease activity index; NSAIDs – Non-Steroidal Anti-Inflammatory Drugs; csDMARDs – conventional synthetic disease modifying anti-rheumatic drugs

Table 2 – Logistic regression on predicting csDMARDs response at month 6
1Age, sex and other variables with p<0.1 are listed. 2 adjusted for age, ESR and VAS pain at baseline. ESR – erythrocyte sedimentation rate; MIP_1β - Macrophage inflammatory protein_1β; VAS – visual analogue scale


Disclosures: I. Cheng, None; H. So, None; M. Li, None; E. Chow, None; C. Wong, None; L. Tam, Janssen, 2, 5, Pfizer, 2, 5, GlaxoSmithKline, 5, AbbVie, 2, Novartis, 5, Amgen, 5, Boehringer Ingelheim, 2, 5, Eli Lilly, 2, Sanofi, 2.

To cite this abstract in AMA style:

Cheng I, So H, Li M, Chow E, Wong C, Tam L. Lower Serum MIP-1β Level Is Associated with CsDMARDs Response in Patients with Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/lower-serum-mip-1%ce%b2-level-is-associated-with-csdmards-response-in-patients-with-early-rheumatoid-arthritis/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lower-serum-mip-1%ce%b2-level-is-associated-with-csdmards-response-in-patients-with-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences